Hairy Cell Leukemia Therapeutics Market Size to Grow by USD 177.85 million, Majority of Growth to Originate from North America – Technavio

NEW YORK, Aug. 22, 2022 /PRNewswire/ — The “Hairy Cell Leukemia Therapeutics Market by Product (Chemotherapy and Targeted therapy) and Geography (North America, Europe, Asia, and Rest of World (ROW)) – Forecast and Analysis 2022-2026″ report has been added to Technavio’s offering. The potential growth difference for the hairy cell leukemia therapeutics market size between 2021 and 2026 is USD 177.85 mn. To get the exact CAGR and the Y-O-Y growth rate, Request a FREE PDF Sample Report.

Key Market Dynamics:
  • Market Driver: The increasing exposure to hazardous substances leading to hairy cell leukemia is driving the growth of the market. Hairy cell leukemia is a rare, slow-growing type of chronic cell leukemia. Cancer occurs when genetic mutations occur in human cells. In the case of hairy cell leukemia, mutations in the DNA lead to the production of excessive white blood cells by bone marrow stem cells. In addition, the overproduced white blood cells function abnormally. The exact cause of this mutation is unknown. Exposure to hazardous substances can occur in occupations such as farming; working in manufacturing plants dealing with hazardous chemicals and fumes; and working in coal mines, cement- and gravel-producing plants, and timber plants that have sawdust. These factors will support the growth of the market.
  • Market Challenge: The limited patient pool will challenge the hairy cell leukemia therapeutics market during the forecast period. The incidence of rare diseases, such as hairy cell leukemia, is lower than other types of cancer. The limited patient pool hinders the evaluation of drug candidates for clinical trials. In addition, many companies have limited R&D budgets. Such contradictions may compel companies to postpone or discontinue the drug development plan for rare diseases.

Technavio offers additional key drivers, trends, and challenges in this report. Buy Now to gain access to exclusive information about the factors impacting the growth of the market

Market Segmentation

The chemotherapy segment will be the largest contributor to market growth during the forecast period. Only a few chemotherapy drugs are approved for the treatment of hairy cell leukemia. However, the treatment type is old when compared to targeted therapies. Hence, the adoption of chemotherapy is higher than targeted therapies.

North America will be the leading region with 40% of the market’s growth during the forecast period. The US and Canada are the key countries for the hairy cell leukemia therapeutics market in North America. The growth of this region is attributed to factors such as sales of approved drugs for the treatment of hairy cell leukemia and the increasing prevalence of various hematologic cancer types. However, market growth in this region will be slower than the growth of the market in other regions.

View our FREE PDF sample report for additional insights into the contribution of all the segments and regional opportunities in the report.

Some Companies Mentioned
  • AbbVie Inc.
  • Amgen Inc.
  • Astex Pharmaceuticals Inc.
  • AstraZeneca Plc
  • Dr. Reddys Laboratories Ltd.
  • F. Hoffmann La Roche Ltd.
  • Fresenius SE and Co. KGaA
  • Hikma Pharmaceuticals Plc
  • Innate Pharma SA
  • Merck KGaA
  • Pfizer Inc.
  • Viatris Inc.

Want your report customized? Speak to an analyst and personalize your report according to your needs

Related Reports

Non-melanoma Skin Cancer Market by Type and Geography – Forecast and Analysis 2022-2026

Anaplastic Thyroid Cancer Drugs Market by Product and Geography – Forecast and Analysis 2022-2026

Hairy Cell Leukemia Therapeutics Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 6.7%

Market growth 2022-2026

USD 177.85 million

Market structure

Concentrated

YoY growth (%)

5.11

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 40%

Key consumer countries

US, Canada, Germany, China, and India

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

AbbVie Inc., Amgen Inc., Astex Pharmaceuticals Inc., AstraZeneca Plc, Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Hikma Pharmaceuticals Plc, Innate Pharma SA, Merck KGaA, Pfizer Inc., and Viatris Inc.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse Health Care Market Reports

Key Topics Covered

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 06: Executive Summary – Chart on Incremental Growth
    • Exhibit 07: Executive Summary – Data Table on Incremental Growth
    • Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 09: Parent market
    • Exhibit 10: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021-2026
    • Exhibit 13: Chart on Global – Market size and forecast 2021-2026 ($ million)
    • Exhibit 14: Data Table on Global – Market size and forecast 2021-2026 ($ million)
    • Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
    • Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

  • 4.1 Five forces summary
    • Exhibit 17: Five forces analysis – Comparison between 2021 and 2026
  • 4.2 Bargaining power of buyers
    • Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026
  • 4.3 Bargaining power of suppliers
    • Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026
  • 4.4 Threat of new entrants
    • Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026
  • 4.5 Threat of substitutes
    • Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026
  • 4.6 Threat of rivalry
    • Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026
  • 4.7 Market condition
    • Exhibit 23: Chart on Market condition – Five forces 2021 and 2026

5 Market Segmentation by Product

  • 5.1 Market segments
    • Exhibit 24: Chart on Product – Market share 2021-2026 (%)
    • Exhibit 25: Data Table on Product – Market share 2021-2026 (%)
  • 5.2 Comparison by Product
    • Exhibit 26: Chart on Comparison by Product
    • Exhibit 27: Data Table on Comparison by Product
  • 5.3 Chemotherapy – Market size and forecast 2021-2026
    • Exhibit 28: Chart on Chemotherapy – Market size and forecast 2021-2026 ($ million)
    • Exhibit 29: Data Table on Chemotherapy – Market size and forecast 2021-2026 ($ million)
    • Exhibit 30: Chart on Chemotherapy – Year-over-year growth 2021-2026 (%)
    • Exhibit 31: Data Table on Chemotherapy – Year-over-year growth 2021-2026 (%)
  • 5.4 Targeted therapy – Market size and forecast 2021-2026
    • Exhibit 32: Chart on Targeted therapy – Market size and forecast 2021-2026 ($ million)
    • Exhibit 33: Data Table on Targeted therapy – Market size and forecast 2021-2026 ($ million)
    • Exhibit 34: Chart on Targeted therapy – Year-over-year growth 2021-2026 (%)
    • Exhibit 35: Data Table on Targeted therapy – Year-over-year growth 2021-2026 (%)
  • 5.5 Market opportunity by Product
    • Exhibit 36: Market opportunity by Product ($ million)

6 Customer Landscape

  • 6.1 Customer landscape overview
    • Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

  • 7.1 Geographic segmentation
    • Exhibit 38: Chart on Market share by geography 2021-2026 (%)
    • Exhibit 39: Data Table on Market share by geography 2021-2026 (%)
  • 7.2 Geographic comparison
    • Exhibit 40: Chart on Geographic comparison
    • Exhibit 41: Data Table on Geographic comparison
  • 7.3 North America – Market size and forecast 2021-2026
    • Exhibit 42: Chart on North America – Market size and forecast 2021-2026 ($ million)
    • Exhibit 43: Data Table on North America – Market size and forecast 2021-2026 ($ million)
    • Exhibit 44: Chart on North America – Year-over-year growth 2021-2026 (%)
    • Exhibit 45: Data Table on North America – Year-over-year growth 2021-2026 (%)
  • 7.4 Europe – Market size and forecast 2021-2026
    • Exhibit 46: Chart on Europe – Market size and forecast 2021-2026 ($ million)
    • Exhibit 47: Data Table on Europe – Market size and forecast 2021-2026 ($ million)
    • Exhibit 48: Chart on Europe – Year-over-year growth 2021-2026 (%)
    • Exhibit 49: Data Table on Europe – Year-over-year growth 2021-2026 (%)
  • 7.5 Asia – Market size and forecast 2021-2026
    • Exhibit 50: Chart on Asia – Market size and forecast 2021-2026 ($ million)
    • Exhibit 51: Data Table on Asia – Market size and forecast 2021-2026 ($ million)
    • Exhibit 52: Chart on Asia – Year-over-year growth 2021-2026 (%)
    • Exhibit 53: Data Table on Asia – Year-over-year growth 2021-2026 (%)
  • 7.6 Rest of World (ROW) – Market size and forecast 2021-2026
    • Exhibit 54: Chart on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
    • Exhibit 55: Data Table on Rest of World (ROW) – Market size and forecast 2021-2026 ($ million)
    • Exhibit 56: Chart on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
    • Exhibit 57: Data Table on Rest of World (ROW) – Year-over-year growth 2021-2026 (%)
  • 7.7 US – Market size and forecast 2021-2026
    • Exhibit 58: Chart on US – Market size and forecast 2021-2026 ($ million)
    • Exhibit 59: Data Table on US – Market size and forecast 2021-2026 ($ million)
    • Exhibit 60: Chart on US – Year-over-year growth 2021-2026 (%)
    • Exhibit 61: Data Table on US – Year-over-year growth 2021-2026 (%)
  • 7.8 Germany – Market size and forecast 2021-2026
    • Exhibit 62: Chart on Germany – Market size and forecast 2021-2026 ($ million)
    • Exhibit 63: Data Table on Germany – Market size and forecast 2021-2026 ($ million)
    • Exhibit 64: Chart on Germany – Year-over-year growth 2021-2026 (%)
    • Exhibit 65: Data Table on Germany – Year-over-year growth 2021-2026 (%)
  • 7.9 China – Market size and forecast 2021-2026
    • Exhibit 66: Chart on China – Market size and forecast 2021-2026 ($ million)
    • Exhibit 67: Data Table on China – Market size and forecast 2021-2026 ($ million)
    • Exhibit 68: Chart on China – Year-over-year growth 2021-2026 (%)
    • Exhibit 69: Data Table on China – Year-over-year growth 2021-2026 (%)
  • 7.10 Canada – Market size and forecast 2021-2026
    • Exhibit 70: Chart on Canada – Market size and forecast 2021-2026 ($ million)
    • Exhibit 71: Data Table on Canada – Market size and forecast 2021-2026 ($ million)
    • Exhibit 72: Chart on Canada – Year-over-year growth 2021-2026 (%)
    • Exhibit 73: Data Table on Canada – Year-over-year growth 2021-2026 (%)
  • 7.11 India – Market size and forecast 2021-2026
    • Exhibit 74: Chart on India – Market size and forecast 2021-2026 ($ million)
    • Exhibit 75: Data Table on India – Market size and forecast 2021-2026 ($ million)
    • Exhibit 76: Chart on India – Year-over-year growth 2021-2026 (%)
    • Exhibit 77: Data Table on India – Year-over-year growth 2021-2026 (%)
  • 7.12 Market opportunity by geography
    • Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

  • 8.1 Market drivers
  • 8.2 Market challenges
  • 8.3 Impact of drivers and challenges
    • Exhibit 79: Impact of drivers and challenges in 2021 and 2026
  • 8.4 Market trends

9 Vendor Landscape

  • 9.1 Overview
  • 9.2 Vendor landscape
    • Exhibit 80: Overview on Criticality of inputs and Factors of differentiation
  • 9.3 Landscape disruption
    • Exhibit 81: Overview on factors of disruption
  • 9.4 Industry risks
    • Exhibit 82: Impact of key risks on business

10 Vendor Analysis

  • 10.1 Vendors covered
    • Exhibit 83: Vendors covered
  • 10.2 Market positioning of vendors
    • Exhibit 84: Matrix on vendor position and classification
  • 10.3 AbbVie Inc.
    • Exhibit 85: AbbVie Inc. – Overview
    • Exhibit 86: AbbVie Inc. – Product / Service
    • Exhibit 87: AbbVie Inc. – Key offerings
  • 10.4 Amgen Inc.
    • Exhibit 88: Amgen Inc. – Overview
    • Exhibit 89: Amgen Inc. – Product / Service
    • Exhibit 90: Amgen Inc. – Key offerings
  • 10.5 AstraZeneca Plc
    • Exhibit 91: AstraZeneca Plc – Overview
    • Exhibit 92: AstraZeneca Plc – Product / Service
    • Exhibit 93: AstraZeneca Plc – Key news
    • Exhibit 94: AstraZeneca Plc – Key offerings
  • 10.6 F. Hoffmann La Roche Ltd.
    • Exhibit 95: F. Hoffmann La Roche Ltd. – Overview
    • Exhibit 96: F. Hoffmann La Roche Ltd. – Business segments
    • Exhibit 97: F. Hoffmann La Roche Ltd. – Key news
    • Exhibit 98: F. Hoffmann La Roche Ltd. – Key offerings
    • Exhibit 99: F. Hoffmann La Roche Ltd. – Segment focus
  • 10.7 Fresenius SE and Co. KGaA
    • Exhibit 100: Fresenius SE and Co. KGaA – Overview
    • Exhibit 101: Fresenius SE and Co. KGaA – Business segments
    • Exhibit 102: Fresenius SE and Co. KGaA – Key news
    • Exhibit 103: Fresenius SE and Co. KGaA – Key offerings
    • Exhibit 104: Fresenius SE and Co. KGaA – Segment focus
  • 10.8 Hikma Pharmaceuticals Plc
    • Exhibit 105: Hikma Pharmaceuticals Plc – Overview
    • Exhibit 106: Hikma Pharmaceuticals Plc – Business segments
    • Exhibit 107: Hikma Pharmaceuticals Plc – Key offerings
    • Exhibit 108: Hikma Pharmaceuticals Plc – Segment focus
  • 10.9 Innate Pharma SA
    • Exhibit 109: Innate Pharma SA – Overview
    • Exhibit 110: Innate Pharma SA – Product / Service
    • Exhibit 111: Innate Pharma SA – Key offerings
  • 10.10 Merck KGaA
    • Exhibit 112: Merck KGaA – Overview
    • Exhibit 113: Merck KGaA – Business segments
    • Exhibit 114: Merck KGaA – Key news
    • Exhibit 115: Merck KGaA – Key offerings
    • Exhibit 116: Merck KGaA – Segment focus
  • 10.11 Pfizer Inc.
    • Exhibit 117: Pfizer Inc. – Overview
    • Exhibit 118: Pfizer Inc. – Product / Service
    • Exhibit 119: Pfizer Inc. – Key news
    • Exhibit 120: Pfizer Inc. – Key offerings
  • 10.12 Viatris Inc.
    • Exhibit 121: Viatris Inc. – Overview
    • Exhibit 122: Viatris Inc. – Business segments
    • Exhibit 123: Viatris Inc. – Key offerings
    • Exhibit 124: Viatris Inc. – Segment focus

11 Appendix

  • 11.1 Scope of the report
  • 11.2 Inclusions and exclusions checklist
    • Exhibit 125: Inclusions checklist
    • Exhibit 126: Exclusions checklist
  • 11.3 Currency conversion rates for US$
    • Exhibit 127: Currency conversion rates for US$
  • 11.4 Research methodology
    • Exhibit 128: Research methodology
    • Exhibit 129: Validation techniques employed for market sizing
    • Exhibit 130: Information sources
  • 11.5 List of abbreviations
    • Exhibit 131: List of abbreviations
About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:[email protected]
Website: www.technavio.com/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hairy-cell-leukemia-therapeutics-market-size-to-grow-by-usd-177-85-million-majority-of-growth-to-originate-from-north-america—technavio-301609487.html

SOURCE Technavio

Hairy Cell Leukemia Therapeutics Market Size to Grow by USD 177.85 million, Majority of Growth to Originate from North America - Technavio WeeklyReviewer

PR Newswire Science News

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

WeeklyReviewer earns commissions through affiliates of qualifying products through Amazon Associates, Fiverr Affiliates, Hostgator Affiliates, Namecheap Affiliates, NordVPN Affiliates, Semrush Affiliates, Alibaba Affiliates, Clickfunnels Affiliate, Leadpages Affiliates, Cryptohopper Affiliates, Binance Affiliates and more.

Clicking on links in WeeklyReviewer may or may not provide us commission through any qualifying purchases.

World Reviewer Staff
World Reviewer Staffhttps://weeklyreviewer.com/
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Related articles

WeeklyReviewer